Lv1
50 积分 2025-01-14 加入
316P Capivasertib (C) + ribociclib (R) + fulvestrant (F) in patients (pts) with HR-positive/HER2-negative advanced breast cancer (ABC): CAPItello-292 phase Ib
1天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
1天前
已完结
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): an open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study
1天前
已完结
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
1个月前
已完结
皖公网安备34019202002308
